Hepatic progenitor cells: Another piece in the nonalcoholic fatty liver disease puzzle
Dawn M. Torres, Stephen A. Harrison – 22 June 2012
Dawn M. Torres, Stephen A. Harrison – 22 June 2012
Natalia De las Heras, Maria‐Angeles Aller, Jaime Arias, Vicente Lahera – 22 June 2012
Salvatore Petta, Antonio Craxì – 22 June 2012
Chung‐Mau Lo – 19 June 2012
Jung Pyo Lee, Hyuk Yong Kwon, Ji In Park, Nam‐Joon Yi, Kyung‐Suk Suh, Hae Won Lee, Myounghee Kim, Yun Kyu Oh, Chun Soo Lim, Yon Su Kim – 19 June 2012 – Liver transplantation (LT) is the treatment of choice for hepatorenal syndrome (HRS). However, the clinical benefits of living donor liver transplantation (LDLT) are not yet well established. We, therefore, investigated the outcomes of patients with HRS who underwent LDLT and patients with HRS who received transplants from deceased donors.
Shao‐Lai Zhou, Zhi Dai, Zheng‐Jun Zhou, Xiao‐Ying Wang, Guo‐Huan Yang, Zheng Wang, Xiao‐Wu Huang, Jia Fan, Jian Zhou – 18 June 2012 – CXCL5 (epithelial neutrophil‐activating peptide‐78) is a member of a proangiogenic subgroup of the CXC‐type chemokine family of small, secreted proteins. Recently, evidence that CXCL5 is involved in carcinogenesis and cancer progression has emerged.
Keunok Jung, Miseon Kang, Cheol Park, Yung Hyun Choi, Youkyung Jeon, Se‐Ho Park, Su‐Kil Seo, Dan Jin, Inhak Choi – 18 June 2012 – V‐set and Ig domain‐containing 4 (VSIG4, CRIg, or Z39Ig), a newly identified B7‐related cosignaling molecule, is a complement receptor and a coinhibitory ligand that negatively regulates T‐cell immunity. Despite its exclusive expression on liver Kupffer cells (KCs) that play key roles in liver tolerance, the physiological role of VSIG4 in liver tolerance remains undefined.
Ji Hoon Yu, Bing‐Mei Zhu, Gregory Riedlinger, Keunsoo Kang, Lothar Hennighausen – 18 June 2012 – Loss of signal transducer and activator of transcription 5 (STAT5) from liver tissue results in steatosis and enhanced cell proliferation. This study demonstrates that liver‐specific Stat5‐null mice develop severe hepatic steatosis as well as hepatocellular carcinomas at 17 months of age, even in the absence of chemical insults. To understand STAT5′s role as a tumor suppressor, we identified and investigated new STAT5 target genes.
Tao Zhang, Junping Zhang, Xiaona You, Qian Liu, Yumei Du, Yuen Gao, Changliang Shan, Guangyao Kong, Youliang Wang, Xiao Yang, Lihong Ye, Xiaodong Zhang – 18 June 2012 – Hepatitis B virus X protein (HBx) plays critical roles in the development of hepatocellular carcinogenesis (HCC). Yes‐associated protein (YAP), a downstream effector of the Hippo‐signaling pathway, is an important human oncogene. In the present article, we report that YAP is involved in the hepatocarcinogenesis mediated by HBx.
Patrick Marcellin, Hugo Cheinquer, Manuela Curescu, Geoffrey M. Dusheiko, Peter Ferenci, Andrzej Horban, Donald Jensen, Gabriella Lengyel, Alessandra Mangia, Denis Ouzan, Massimo Puoti, Maribel Rodriguez‐Torres, Mitchell L. Shiffman, Manuela Schmitz, Fernando Tatsch, Mario Rizzetto – 18 June 2012 – The ability to predict which patients are most likely to achieve a sustained virologic response (SVR) with peginterferon/ribavirin would be useful in optimizing treatment for hepatitis C virus (HCV).